drugset / Trial / NCT07586202
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal growth factor receptor (EGFR) mutated, Stage II-IIIB non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. NSCLC may occur due to mutations (changes) in many genes, including EGFR.
Timeline
- Start
- 2026-07-17
- Primary completion
- 2028-03-02
- Completion
- 2028-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amivantamab | Monoclonal antibody | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Lazertinib | Small molecule | — | — |
| Subject | Pemetrexed | Small molecule | — | — |